Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Recurrence × talquetamab × Clear all

Status

Recruiting 1 Completed 1 Approved for marketing 1 Active not recruiting 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

ibrutinib 2 vorasidenib 1 talquetamab 1 pomalidomide 1 fludarabine 1 brexucabtagene autoleucel 1 axicabtagene ciloleucel 1 Cyclophosphamide 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Approved for marketing

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡